Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $17.6 million.

  • 10x Genomics' Change in Accured Expenses rose 29977.27% to $17.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.6 million, marking a year-over-year increase of 16004.24%. This contributed to the annual value of $7.6 million for FY2025, which is 16004.24% up from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Change in Accured Expenses is $17.6 million, which was up 29977.27% from -$2.1 million recorded in Q3 2025.
  • 10x Genomics' 5-year Change in Accured Expenses high stood at $19.5 million for Q3 2023, and its period low was -$15.1 million during Q1 2023.
  • In the last 5 years, 10x Genomics' Change in Accured Expenses had a median value of $4.2 million in 2024 and averaged $2.1 million.
  • Per our database at Business Quant, 10x Genomics' Change in Accured Expenses tumbled by 21681.47% in 2021 and then skyrocketed by 65156.7% in 2022.
  • Quarter analysis of 5 years shows 10x Genomics' Change in Accured Expenses stood at $4.5 million in 2021, then surged by 45.42% to $6.5 million in 2022, then soared by 194.63% to $19.1 million in 2023, then plummeted by 77.03% to $4.4 million in 2024, then surged by 299.77% to $17.6 million in 2025.
  • Its last three reported values are $17.6 million in Q4 2025, -$2.1 million for Q3 2025, and $3.9 million during Q2 2025.